Oncology Drugs Global Market Report 2018

Oncology Drugs Global Market Report 2018
Starting Price : $ 4000.00 | Pages : 125 | Published : February 2018

SKU CODE : 3259 | Format :

Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors. These drugs prevent the growth of malignant tumors by affecting the process of cell division or by damaging the DNA and initiate apoptosis or by preventing the development and spread of neoplastic cells. Several types of cancers that can be treated by oncology drugs are blood cancer, lung cancer, endocrine cancer, bone cancer, gastric cancer, colorectal cancer, skin cancer, breast cancer, pancreatic cancer, prostate cancers, ovarian cancer, ocular cancer and others.

North America was the largest region in the oncology drugs market in 2017, accounting for 31% market share. North America has the highest GDP that allows it to afford the latest and patented oncology medicines which are comparatively higher or difficult to access when compared with other regions.  
North America has a higher number of cancer patients. In 2012, approximately 1.8 million new cases were registered across North America. This can be considered as a major factor attributing to North America’s highest oncology drugs market share. Asia Pacific was the second largest region accounting for 25% market share. Middle East was the smallest region accounting for 4% market share.

Companies are increasingly using cancer biomarkers in the drug development process. Cancer biomarkers are molecules secreted by a tumor or a specific response of the body to the presence of cancer. Identifying and targeting these can enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics tools. It can also help predict the drug efficacy faster than conventional clinical endpoints, the point at which an undesired or abnormal effect of the drug is observed indicating withdrawal from therapy. Companies in this market are investing in the development of biomarkers for use in various activities such as tracking drug activity, the pharmacodynamics of drugs and to study diseases and treatment pathways. For instance, Nektar Therapeutics is developing and using biomarkers in drug development processes of its pipeline drugs NKTR-214 and NKTR-181. Janssen’s research & development is also focusing on identifying predictive markers or stratification markers to help target the new therapies.

Pharmaceutical Drugs Global Market Report 2018

Pharmaceutical Drugs Global Market Report 2018

Contract Research Organizations Global Market Report 2018

Pharmaceutical Drugs Global Market Report 2018

Contract Research Organizations Global Market Report 2018

Biologics Global Market Report 2018

Minor Orthopedic Replacement Implants Global Market Report 2018

Minor Orthopedic Replacement Implants Global Market Report 2018

Organ-On-Chip Global Market 2018

View Report

Organ-On-Chip Global Market 2018

View Report

Organ-On-Chip Global Market 2018

View Report

Organ-On-Chip Global Market 2018

View Report

Organ-On-Chip Global Market 2018

View Report

Bio-Pharmaceutical Logistics Global Market Report 2018

View Report

Bio-Pharmaceutical Logistics Global Market Report 2018

View Report

Bio-Pharmaceutical Logistics Global Market Report 2018

View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)